| Range | 37.00 - 37.00 |
| 52 week | 30.00 - 117.20 |
| Open | 37.00 |
| Vol / Avg. | 24,000.00/15,341.00 |
| Mkt cap | 48.36M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.27* |
| Shares | 130.71M |
| Beta | - |
| Inst. own | - |
| *GBP |
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -7.66% | -41.54% |
| Operating margin | -11.60% | -40.01% |
| EBITD margin | - | -30.27% |
| Return on average assets | -4.50% | -24.84% |
| Return on average equity | 0.04% | -43.77% |
| Employees | 583 | - |
| Carbon Disclosure Rating | - | - |
| Steve Melton | Chief Executive Officer | |
| Paolo Pieri | Chief Financial Officer, Executive Director | |
| Massoud Keyvan-Fouladi | Chief Medical Officer, Executive Director | |
| Michael James Kirkwood | Non-Executive Independent Chairman of the Board | |
| Timothy Bunting | Non-Executive Director | |
| Ali Parsadoust | Non-Executive Director | |
| Jamie P. Wood | Non-Executive Director | |
| Lorraine Baldry | Senior Non-Executive Independent Director |